Recombinant Biotinylated Human Her2 / ErbB2, ultra sensitivity (primary amine labeling, long spacer), His-Tag, 25 µg

Background
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation.

Source
MABSol® Recombinant Biotinylated Human Her2, His Tag, primary amine labeling, long spacer (HE2-H822R) is expressed from human HEK293 cells. It contains AA Thr 23 - Thr 652 (Accession # P04626-1). It is the biotinylated form of Human Her2, His Tag (Cat. No. HE2-H5225).
Predicted N-terminus: Thr 23

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.2 kDa. The protein migrates as 85-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A specially optimized long-spacer biotin reagent (32.5 angstroms) is used in this product to minimize potential steric hindrance.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.

Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70^°C for 12 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft"
Zhang, Li, Liao et al
Cell Death Discov (2022) 8 (1), 478
(2) "Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study"
de la Cruz-Merino, Gion, Cruz et al
BMC Cancer (2022) 22 (1), 1258
(3) "Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer"
Miser-Salihoglu, Demokan, Karanlik et al
Clin Breast Cancer (2022)
Showing 1-3 of 37486 papers.

Citations

(1) "The Impact of FcγRI Binding on ImmunoPET"
Authors: Vivier D, et al
Journal: J NUCL MED 2019
Application: SPR
(2) "Small-molecule probes for affinity-guided introduction of biocom-patible handles on metal-binding proteins"
Authors: Mortensen MR, et al.
Journal: Bioconjug Chem 2018
Application: SPR
(3) "Antibody-drug conjugate having improved stability and use thereof"
Authors: Kim Young Min, et al.
Journal: US20160136300A1 2016
Application: ELISA